Immusoft

Recent Finacing

Grant

Recent Raise

$8M

Immusoft develops an ex vivo, non‑viral Immune System Programming platform that reprograms autologous B cells via Sleeping Beauty transposon to continuously secrete therapeutic proteins; lead program ISP‑001 targets MPS I.